Pharmacokinetic advantage of intra-arterial cyclosporin A delivery to vascularly isolated rabbit forelimb. II. Dose dependence
- PMID: 10336505
Pharmacokinetic advantage of intra-arterial cyclosporin A delivery to vascularly isolated rabbit forelimb. II. Dose dependence
Abstract
A vascularly isolated rabbit forelimb model simulating conditions of composite tissue allografting was used to determine the regional pharmacokinetic advantage achievable in extremity tissue components during i.a. cyclosporin A (CSA) administration. CSA was infused continuously via osmotic minipump into the right brachial artery of New Zealand rabbits at multiple doses ranging from 1.0 to 8.0 mg/kg/day. On day 6, CSA concentrations were measured in aortic whole blood, as well as in skin, muscle, bone, and bone marrow samples from both right and left forelimbs. The variation of right-sided mean CSA concentrations with dose was tissue dependent and saturable in the case of skin and bone, whereas left-sided tissue concentrations correlated significantly with systemic blood levels. At 1.0 mg/kg/day, there were no significant differences between right and left mean CSA concentrations for all four tissues examined. However, with a doubling of the i.a. dose, huge increases in local tissue CSA concentrations were produced with only very modest increases in systemic whole-blood and tissue drug levels, resulting in a 4-fold regional advantage (right/left ratio of CSA concentrations) in bone and bone marrow, 7-fold in muscle, and 14-fold in skin. With further dose increases to 8.0 mg/kg/day, the regional advantage decreased to 4-fold in skin, increased to 9-fold in bone marrow, remained relatively constant in bone, and initially decreased and then increased to 9-fold in muscle. These favorable pharmacokinetic results suggest that reduced, local doses of CSA might be useful in preventing extremity composite tissue allograft rejection with decreased systemic drug exposure.
Similar articles
-
Pharmacokinetics of intra-arterial delivery of tacrolimus to vascularly isolated rabbit forelimb.J Pharmacol Exp Ther. 1999 Jun;289(3):1196-201. J Pharmacol Exp Ther. 1999. PMID: 10336506
-
Pharmacokinetic advantage of intra-arterial cyclosporin A delivery to vascularly isolated rabbit forelimb. I. Model development.J Pharmacol Exp Ther. 1999 Jun;289(3):1185-90. J Pharmacol Exp Ther. 1999. PMID: 10336504
-
Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.Bone Marrow Transplant. 2000 Sep;26(5):545-51. doi: 10.1038/sj.bmt.1702545. Bone Marrow Transplant. 2000. PMID: 11019845
-
New oral formulation of cyclosporin A (Neoral) pharmacokinetics in allogeneic bone marrow transplant recipients.Bone Marrow Transplant. 2000 May;25(9):965-8. doi: 10.1038/sj.bmt.1702375. Bone Marrow Transplant. 2000. PMID: 10800064 Clinical Trial.
-
[The effect of tetramethylpyrazine on the pharmacokinetics of intragastrically administered cyclosporine A in rats].Yao Xue Xue Bao. 2006 Sep;41(9):882-7. Yao Xue Xue Bao. 2006. PMID: 17111838 Chinese.
Cited by
-
Site-specific immunosuppression in vascularized composite allotransplantation: prospects and potential.Clin Dev Immunol. 2013;2013:495212. doi: 10.1155/2013/495212. Epub 2013 Feb 13. Clin Dev Immunol. 2013. PMID: 23476677 Free PMC article. Review.